08.10.10
Sanofi-Aventis and Scripps Genomic Medicine (SGM) entered a strategic alliance to advance R&D initiatives in the field of personalized medicine.
Under the alliance, SA’s R&D unit will fund as many as three discovery innovation grants per year, aimed at providing flexible financing for research proposals from Scripps investigators. In turn, SA will be granted non-exclusive rights to any research tools developed through these grants, as well as access to Scripps lab facilities in support of sponsored research agreements, technologies or discoveries in the field of personalized medicine. Additionally, through scientific exchange and collaboration including an Annual Research Symposium jointly organized by SA and Scripps, SA will have access to Scripps research programs that can contribute to the company's priority areas.
"Our alliance with Sanofi-Aventis exemplifies the ideal collaboration between the pharmaceutical industry and non-profit research community," said Dr. Eric Topol, chief academic officer of Scripps. "The partnership aims to foster an environment of open scientific exchange in genomic medicine that we hope will translate to new discoveries to benefit patients while establishing a collaborative approach to drug development."
"Our alliance with Scripps underscores Sanofi-Aventis' commitment to collaborating with a range of innovative partners focused on cutting-edge scientific research and development initiatives," said Marc Cluzel, M.D., Ph.D., executive vice president, R&D, Sanofi-Aventis. "Personalized medicine, particularly the application of genomics, has the potential to vastly improve patient health.This partnership seeks to significantly enhance our research activities in this important field."
Under the alliance, SA’s R&D unit will fund as many as three discovery innovation grants per year, aimed at providing flexible financing for research proposals from Scripps investigators. In turn, SA will be granted non-exclusive rights to any research tools developed through these grants, as well as access to Scripps lab facilities in support of sponsored research agreements, technologies or discoveries in the field of personalized medicine. Additionally, through scientific exchange and collaboration including an Annual Research Symposium jointly organized by SA and Scripps, SA will have access to Scripps research programs that can contribute to the company's priority areas.
"Our alliance with Sanofi-Aventis exemplifies the ideal collaboration between the pharmaceutical industry and non-profit research community," said Dr. Eric Topol, chief academic officer of Scripps. "The partnership aims to foster an environment of open scientific exchange in genomic medicine that we hope will translate to new discoveries to benefit patients while establishing a collaborative approach to drug development."
"Our alliance with Scripps underscores Sanofi-Aventis' commitment to collaborating with a range of innovative partners focused on cutting-edge scientific research and development initiatives," said Marc Cluzel, M.D., Ph.D., executive vice president, R&D, Sanofi-Aventis. "Personalized medicine, particularly the application of genomics, has the potential to vastly improve patient health.This partnership seeks to significantly enhance our research activities in this important field."